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Global framework on essential health R&D
One of the critical issues to be discussed at the next 
World Health Assembly (Geneva, May 22–26) will be 
a resolution about a global framework on essential 
health research and development.1 Over past years, the 
crisis in research and development in the worldwide 
pharmaceutical industry, and in particular the absence of 
research and development for new medicines targeting 
diseases that mainly aﬀ ect people in developing 
countries (neglected diseases), has become a global 
concern.2
This worrying situation is clearly shown by the number 
of drugs targeting neglected tropical diseases. From 1975 
to 1999, only 13 drugs from 1393 new chemical entities 
(NCE) marketed were indicated for a neglected disease.3,4 
The 13 drugs included four for malaria and nine for the 
most neglected diseases. Three more drugs could be added 
if tuberculosis is included in the analysis (table).4
We have updated these ﬁ gures to 2004. From 2000 
to 2004, an additional 163 NCEs have been marketed 
in the world, adding up to a total of 1556 NCEs for the 
30 years from 1975 to 2004.5 During these 5 years, 
four NCEs targeting neglected diseases have been 
commercialised (table). Artemotil is a derivative from 
artemisinine discovered in the Chinese traditional 
medicine Artemisia annua. Artemotil is available as 
injection for severe malaria.6 Artesunate is another 
derivative from artemisinine. Artesunate should be used 
only in combination (artemisinin-based combination 
therapy) to treat malaria. Diﬀ erent co-blisters containing 
artesunate with a partner drug (existing antimalarials 
such as sulfadoxine/pyrimethamine, amodiaquine, 
meﬂ oquine) are available on the market. Furthermore, 
several co-formulations containing artesunate and the 
partner drug in the same tablet are being developed.7,8 
Lumefantrine is marketed as a co-formulation with 
artemether, also a derivative from artemisinine.9 
Miltefosine is the ﬁ rst oral dug against leishmaniasis.10 
The combination of chlorproguanil with dapsone 
(Lapdap) has also been launched during the past years. It 
is not a NCE, but there has been research on this drug.11
In total, over the past 30 years, the number of drugs 
targeting neglected diseases is ten if we consider the most 
neglected diseases, 18 if we add malaria, and 21 if we add 
tuberculosis. These totals still represent only around 1% of 
Products 
1975–99 2000–04
Malaria Atovaquone Artemotil
Artemether Artesunate
Halofantine hydrochloride Lumefantrine
Meﬂ oquine Chlorproguanil+dapsone*
Chagas’ disease Benznidazole ..
Nifurtimox ..
Helminthic infections Albendazole ..
Human African trypanosomiasis Eﬂ ornithine ..
Pentamidine isetionate* ..
Leishmaniasis Liposomal amphotericin B* Miltefosine
Onchocerciasis Ivermectin ..
Schistosomiasis Oxamniquine ..
Praziquantel ..
Tuberculosis Pyrazinamide ..
Rifabutin ..
Rifapentine ..
Total 16 5
*These drugs are not new chemical entities but new salt, formulation, or combination.
Table: Number of new drugs targeting neglected diseases
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all NCEs (1556) launched during this period—a situation 
that is essentially unchanged from 5 years ago.
The emergence of product-development partnerships 
for neglected diseases has been encouraging: with 
suﬃ  cient funding the current pipelines for neglected 
diseases could potentially deliver eight to nine drugs 
within the next 5 years.12 Although such a step forward 
would be good, it is not enough to change the overall 
situation. Product-development partnerships in drug 
research and development for neglected diseases 
still mainly depend on philanthropic funding, which 
reached US$212 million by April, 2005, or 78·5% of the 
total funding of these initiatives, much of it from the 
Bill & Melinda Gates Foundation. Public funding was 
calculated at a low 16%, although the British Government 
in March, 2006, announced substantial additional funding 
worth £17 million (or about $30 million). With promising 
drug compounds moving into more expensive clinical 
trials, there remains a funding gap of several hundred 
million dollars for existing initiatives alone.12
There is deﬁ nitely a proactive role for WHO to play here, 
because only a long-term commitment by governments 
to fund and otherwise support research and development 
in neglected diseases in the public interest would sub-
stantially change the situation of neglected diseases and 
neglected patients.
The report of the WHO’s Commission on Intellectual 
Property Rights, Innovation, and Public Health, released 
April 3, 2005, is urging WHO to “develop a Global Plan of 
Action to secure enhanced and sustainable funding for 
developing and making accessible products to address 
diseases that disproportionately aﬀ ect developing coun-
tries”.13 The World Health Assembly’s discussion in May 
on a global framework on research and development 
in essential health will be a timely opportunity for 
governments to take action to ensure needs-driven 
research and development addressing rich and poor 
patients’ needs. Member states should warmly welcome 
the resolution on research and development and start 
building a new framework on research and development 
for essential health.
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For a whole month from June 9 of this year civilised activity 
and conversation will be silenced by the quadrennial 
competition for association football’s World Cup, the Jules 
Rimet trophy, in which 32 national teams will try to slot 
an air-ﬁ lled plastic sphere through a rectangle measuring 
2·4 by 7·2 m. This is not as easy as it sounds. For example, 
on Saturday, March 18, one-third of the sides competing 
in the top nine English and Scottish football leagues 
did not succeed once during 90 min of endeavour. Even 
with no goals and despite many unattractive features, on 
and oﬀ  the ﬁ eld, this is still called “the beautiful game”. 
The wall set up against a direct free kick is anything but 
elegant, with its serried row of defenders blocking the 
straight path to goal and nervously protecting other 
sensitive sites with hands (when male) crossed below the 
waistband. There is a counter to this ploy, the banana kick, 
Jules Rimet’s bananas
